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Community-associated methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) strains have emerged in Uruguay. 
We reviewed S. aureus isolates from a large healthcare facil-
ity in Montevideo (center A) and obtained information from 3 
additional hospitals on patients infected with CA-MRSA. An 
infection was deﬁ  ned as healthcare-onset if the culture was 
obtained >48 hours after hospital admission. At center A, the 
proportion of S. aureus infections caused by CA-MRSA in-
creased from 4% to 23% over 2 years; the proportion caused 
by healthcare-associated MRSA (HA-MRSA) decreased 
from 25% to 5%. Of 182 patients infected with CA-MRSA, 38 
(21%) had healthcare-onset infections. Pulsed-ﬁ  eld gel elec-
trophoresis determined that 22 (92%) of 24 isolates were 
USA1100, a community strain. CA-MRSA has emerged in 
Uruguay and appears to have replaced HA-MRSA strains at 
1 healthcare facility. In addition, CA-MRSA appears to cause 
healthcare-onset infections, a ﬁ  nding that emphasizes the 
need for infection control measures to prevent transmission 
within healthcare settings.
M
ethicillin-resistant Staphylococcus aureus (MRSA) 
was recognized as a nosocomial pathogen in the 
1960s and now represents a substantial proportion of 
S. aureus infections in inpatient and outpatient settings 
(1,2). Risk factors for healthcare-associated MRSA (HA-
MRSA) are well deﬁ   ned and include hospitalization, 
surgery, dialysis, residence in a long-term care facility, 
and use of indwelling catheters or other percutaneous 
medical devices (3,4).
During the 1990s, MRSA emerged as a cause of in-
fection among healthy persons in the community who had 
none of the above HA-MRSA risk factors (5–10). Commu-
nity-associated MRSA (CA-MRSA) infections most com-
monly manifest as skin and soft tissue infections, but more 
invasive infections, including sepsis syndrome, necrotizing 
pneumonia, and fasciitis, also occur (11,12). Outbreaks 
of CA-MRSA infection have occurred among prisoners, 
sports participants, military recruits, and healthy full-term 
newborns (7–9). In a population-based study in Atlanta and 
Baltimore, the incidence of CA-MRSA infection was high-
est among children <2 years old (11). Factors that appear 
to facilitate transmission of CA-MRSA include frequent 
skin-to-skin contact, crowding, compromised skin integ-
rity, sharing of potentially contaminated items, and lack of 
personal hygiene.
HA-MRSA and CA-MRSA possess resistance to 
β-lactam antimicrobial agents, conferred by the staphy-
lococcal cassette chromosome (SCC) mec element (13). 
However, CA-MRSA strains are typically less resistant 
to non–-β-lactam antimicrobial agents (14). CA-MRSA 
strains almost invariably contain a particular SCCmec type 
(SCCmec IV, V, or VI), whereas HA-MRSA strains usu-
ally contain SCCmec types I, II, or III (15–18). CA-MRSA 
strains typically possess the Panton-Valentine leukocidin 
(PVL) toxin, which has been associated with skin abscesses 
and necrotizing pneumonia (19).
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CA-MRSA has been reported worldwide, and several 
reports describe the entrance of CA-MRSA strain types 
into healthcare settings (20–22). However, few articles 
have documented CA-MRSA emergence in South America 
(23,24). The objectives of this investigation were to de-
scribe trends in S. aureus and MRSA infections in Uru-
guay, to explore transmission of these strains in healthcare 
settings, and to characterize CA-MRSA strains circulating 
in Uruguay.
Methods
Deﬁ  nitions
In this investigation, we deﬁ  ned a case of MRSA in-
fection as illness compatible with staphylococcal disease 
in a patient from whom a strain of S. aureus resistant to 
oxacillin by disk diffusion was isolated from a clinically 
relevant site. Because it was suspected that community 
strains had entered the healthcare setting, epidemiologic 
risk factor data were not useful in distinguishing commu-
nity versus healthcare strains. Therefore, microbiologic 
deﬁ  nitions were used. A MRSA isolate was considered 
to be an HA-MRSA strain if it was resistant to at least 2 
of the following antimicrobial agents: trimethoprim/ sul-
famethoxazole (TMP/SMX), ciproﬂ  oxacin, gentamicin, ri-
fampin, and tetracycline. A MRSA isolate was considered 
to be a CA-MRSA strain if 1) antimicrobial susceptibility 
results were available for at least 2 of the following agents: 
TMP/SMX, ciproﬂ  oxacin, gentamicin, rifampin, tetracy-
cline, and 2) the isolate was resistant to no more than 1 of 
the agents and was conﬁ  rmed to be susceptible to at least 2 
of these agents.
We considered an infection to be healthcare onset if the 
MRSA culture was obtained >48 hours after a patient was 
admitted to the hospital and the patient had no evidence 
of the infection at the time of admission. A MRSA culture 
obtained within 48 hours of hospital admission or evidence 
of infection on admission was considered an indication of a 
community-onset infection.
Skin disease was deﬁ  ned as a primary skin infection 
such as abscess, cellulitis, folliculitis, or a skin infection 
spreading to contiguous tissues. Surgical site infections 
(SSIs) were not considered to be skin disease.
Assessment of Temporal Trends
To describe trends in S. aureus and MRSA infections, 
we reviewed laboratory records from August 2002 through 
July 2004 from a large healthcare facility (center A) that 
provided inpatient, outpatient, emergency, and long-term–
care services to nearly 200,000 persons of all ages and 
socioeconomic levels. Reports of all S. aureus cultures, 
except nasal swabs (to exclude asymptomatic colonized 
patients), were included. Only the ﬁ  rst culture was selected 
for each patient over the study period. Of the total number 
of S. aureus infections, the percentage due to MRSA was 
calculated for each quarter year of the study. Similarly, of 
the MRSA infections, the percentages caused by CA-MR-
SA and HA-MRSA were calculated for each quarter year. 
Chi-square tests for trend were calculated by using SAS 
version 9.1 software (SAS, Cary, NC, USA).
Assessment of Healthcare Transmission
To explore transmission of CA-MRSA strains in hos-
pitals and describe factors associated with transmission, 
we reviewed medical records of patients with CA-MRSA 
infections who were hospitalized between January 2003 
and August 2004 at 4 facilities in Uruguay, centers A–D. 
Centers A and B were prepaid health maintenance organi-
zations serving a heterogenous population of all ages and 
socioeconomic status. Centers C and D were large public 
referral hospitals serving a population of lower socioeco-
nomic status. Center D was a pediatric hospital. At center 
A, we identiﬁ  ed cases by reviewing laboratory records (in-
cluding susceptibility data) of clinical S. aureus isolates (see 
Assessment of Temporal Trends). In the other 3 centers, 
microbiologists and infectious disease physicians provided 
a list of patients with MRSA infections. We identiﬁ  ed the 
patients who met our microbiologic case deﬁ  nition by re-
viewing the patients’ laboratory records. Demographic and 
clinical data were abstracted from patient records by using 
a standardized form. Screening all patients for MRSA was 
not standard practice in any of the facilities included in this 
study.
Data collected included age, sex, location of residence 
(capital city of Montevideo vs. other locations), underly-
ing medical conditions (chronic bronchitis, heart disease or 
stroke, liver or kidney disease, diabetes, HIV, AIDS, or his-
tory of immunosuppression or cancer), infection site (skin 
vs. non-skin), intensive care unit (ICU) admission, and on-
set of infection (hospital vs. community).
Data Analysis
We performed multivariable analysis by using logistic 
regression to determine characteristics independently asso-
ciated with healthcare-onset CA-MRSA strain type infec-
tions. Variable screening was performed by using univari-
ate logistic regression with an α signiﬁ  cance level of 0.25. 
Variables that met the screening criteria were entered in 
a multivariable model and retained with an α signiﬁ  cance 
level of 0.05. Variables that failed to meet screening criteria 
were assessed as potential confounders by using β estimate 
changes of >15% as the criteria. We also assessed effect 
modiﬁ  cation between facility and infection site, facility 
and age, and infection site and age.
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Laboratory Characterization of CA-MRSA Strains
Microbiologists and infectious disease physicians in 
Uruguay had a list of available isolates from patients in-
fected with MRSA. We selected a convenience sample of 
24 isolates from this list to obtain different clinical mani-
festations (skin and systemic infections), patient charac-
teristics (pediatric and adult), treatment settings (inpatient 
and outpatient), healthcare institutions, and community 
and healthcare-onset disease. All isolates were from pa-
tients whose disease met our microbiologic deﬁ  nition of 
CA-MRSA disease. Isolates were sent to the Division of 
Healthcare Quality Promotion staphylococcal reference 
laboratory at the Centers for Disease Control and Prevention 
(CDC, Atlanta, GA, USA). After initially being screened 
for oxacillin resistance, isolates were tested for antimicro-
bial susceptibility by broth microdilution, according to the 
Clinical and Laboratory Standards Institute (25). In addi-
tion, antimicrobial-susceptibility disk tests were performed 
to study inducible clindamycin resistance (25). A PCR was 
used to characterize the SCCmec resistance complex and to 
detect the genes encoding the PVL cytotoxin, toxic shock 
syndrome toxin 1, and enterotoxins A–E and H (15,26). 
Pulsed-ﬁ  eld gel electrophoresis (PFGE) was performed on 
restriction digests of chromosomal DNA (by using SmaI 
restriction endonuclease); gels were analyzed with BioNu-
merics software according to published criteria (27).
Results
Trends in S. aureus and MRSA Infections (center A)
Of 1,553 S. aureus infections at the health maintenance 
organization facility (center A), 42% were cultured in the 
hospital setting, 14% in the emergency department, 42% 
ambulatory care, and 2% from long-term-care service. The 
patients’ median age was 56 years, and 55% were male. 
The proportion of S. aureus infections caused by MRSA re-
mained stable over the 2-year period (χ2 for trend p = 0.46), 
averaging 28% (Figure 1). CA-MRSA strains increased 
from 4% to 23% of all S. aureus infections (χ2 for trend 
p<0.0001) over the 2-year study period, whereas the pro-
portion caused by HA-MRSA decreased from 25% to 5% 
(χ2 for trend p<0.0001) (Figure 2).
CA-MRSA Infections among Patients Hospitalized in 4 
Facilities (centers A–D)
Of the hospitalized patients with CA-MRSA in the 4 
facilities, 59% were male, 80% were from  Montevideo, 
and 29% had an underlying chronic medical condition (Ta-
ble 1). Most infections were of the skin (63%), followed by 
respiratory infections (13%), bacteremias (9%), and SSIs 
(9%) (Table 2).
Of 182 study patients, 38 (21%) were considered to 
have healthcare-onset infections. The age distribution of 
the healthcare-onset and community-onset groups differed 
with median ages of 59 and 7 years, respectively (Figure 3). 
Twenty percent of the community-onset group was <2 years 
of age compared with 3% in the healthcare-onset group. In-
fection site also differed between the healthcare-onset and 
community-onset groups; skin infections dominated the 
community-onset group, whereas most healthcare-onset 
infections were SSIs or respiratory tract infections (Table 
2). ICU admission was more common in the healthcare-
onset than in the community-onset group (61% and 19%, 
respectively, p<0.05) (Table 1).
In multivariable modeling, after the facility was con-
trolled for, age >18 years (odds ratio [OR] 4.8) and non-
skin infection sites (OR 5.1) were independently associated 
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Figure 1. Number of Staphylococcus aureus and methicillin-
resistant S. aureus (MRSA) infections by quarter and year, center 
A, August 2002–July 2004. N = 1,553.
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Figure 2. Proportion of Staphylococcus aureus due to community-
associated methicillin-resistant S. aureus (CA-MRSA) infections 
and healthcare-associated MRSA (HA-MRSA) infections by quarter 
and year, center A, August 2002–July 2004.Community Strains of MRSA, Uruguay
with healthcare-onset CA-MRSA strain type infections 
(Table 1). Effect modiﬁ  cation between facility and infec-
tion site, facility and age, and infection site and age was 
not signiﬁ  cant.
Characterization of CA-MRSA Strains
Of 24 isolates selected for molecular typing and 
toxin testing, 15 (63%) were associated with skin infec-
tions, 5 (21%) bloodstream, 3 (13%) respiratory, and 1 
(4%) a catheter-site infection. One third of the patients 
were <18 years of age (3 were <2 years of age), and 50% 
were female. Nineteen (79%) patients were initially seen 
at hospitals, 3 (13%) at outpatient centers, and 2 (8%) at a 
prison. Three (13%) were considered to have healthcare-
onset infections.
Twenty-two (92%) of the 24 isolates were of PFGE 
type USA1100, a community strain (28). These 22 isolates 
contained SCCmec type IVc and the PVL locus, and 19 of 
the 22 had indistinguishable SmaI PFGE patterns. The oth-
er 3 USA1100 isolates were at least 91% related to the ho-
mogeneous group. The 3 healthcare-onset infections were 
of PFGE type USA1100. The 2 non-USA1100 isolates had 
microbiologic properties consistent with HA-MRSA be-
longing to PFGE type USA600 and USA800—one from 
the respiratory tract and the other from a catheter site. Both 
of these isolates were from adult patients who were consid-
ered to have community-onset infections.
Discussion
In summary, in at least 1 healthcare facility in Uruguay, 
CA-MRSA strains appears to be replacing HA-MRSA 
strains. Transmission of infections caused by CA-MRSA 
strain types appeared to be occurring in the hospital as well 
as the community, and patients whose infections developed 
in the hospital were older and more likely to have non-skin 
infections than those with community-onset disease.
In the United States, according to the National Noso-
comial Infections Surveillance System, MRSA rates have 
risen during the 1990s and early 2000s (1). Klevens et al. 
(2) demonstrated that the antimicrobial resistance proﬁ  le of   
ICU MRSA isolates from this surveillance system changed 
from 1992 through 2003. MRSA consistent with HA-MR-
SA strain types decreased from 55% in 1992 to 10% in 
2003, while CA-MRSA strain types increased from 4% to 
14% during the same period. This resistance pattern change 
was also described in Europe over an 11-year period (1992–
2002) in France and over a 4-year period (1995–1998) in 
Belgium (29,30). In our study, although the proportion of 
S. aureus infections caused by MRSA remained stable, we 
observed a dramatic increase (4% to 23%) in the proportion 
of MRSA consistent with CA-MRSA strain types at 1 large 
healthcare institution in Uruguay. Whether the proportion 
of S. aureus due to MRSA remains stable or starts to in-
crease over time should be monitored.
Healthcare-onset infections of MRSA are typically 
caused by HA-MRSA strain types. However, since the 
emergence of CA-MRSA strains, nosocomial transmission 
of CA-MRSA strains has been documented. Saiman et al. 
(20) described nosocomial transmission in an outbreak set-
ting among postpartum women in New York City and in 
San Francisco. Carleton et al. (31) found a proportion of 
nosocomial MRSA isolates with molecular typing consis-
tent with community strains. In Atlanta, during a 7.5-month 
prospective study in 2004, Seybold et al. (21) found that 
20% of nosocomial MRSA bloodstream infections were 
due to USA300, a CA-MRSA strain type. In our study, 38 
(21%) hospitalized patients with CA-MRSA strain type 
infections met our deﬁ  nition for having healthcare-onset 
infections.
The virulence and transmissibility of CA-MRSA 
strains in the hospital, compared with that of HA-MRSA 
strains, are unknown. CA-MRSA strains are typically 
susceptible to more antimicrobial agents than HA-MRSA 
strains, but this situation may change as CA-MRSA strains 
in the healthcare setting are exposed to high antimicrobial 
selection pressures. In addition, CA-MRSA strains  may 
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Table 1. Association of factors with healthcare- versus community-onset CA-MRSA, hospitalized patients, centers A–D, Uruguay, 
2003–2004*†
Factors 
Total no. (%), 
N = 182 
Healthcare-
onset, no. (%),  
n = 38 
Community-
onset, no. (%), 
n = 144 
Univariate odds of 
healthcare-onset 
(95% CI) 
Multivariate odds 
of healthcare-
onset (95% CI)† 
Age >18 y‡  79 (44)  33 (89)  46 (32)  17.4 (5.8–52.0)  4.8 (1.2–18.7) 
Male 107 (59)  26 (68)  81 (56)  1.7 (0.8–3.6) 
Residence outside Montevideo§  31 (20)  5 (15)  26 (21)  0.7 (0.2–1.9) 
Chronic medical condition¶  51 (29)  21 (57)  30 (22)  4.7 (2.2–10.2) 
Infection site, nonskin  68 (37)  31 (82)  37 (26)  12.8 (5.2–31.5)  5.1 (1.7–15.1) 
Intensive-care unit admission  51 (28) 23 (61)  28 (19)  6.4 (2.9–13.7) 
*CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus; CI, confidence interval.
†Controlling for facility. 
‡n = 180; age not available for 2 patients. 
§n = 159; location of residence not available for 23 patients. 
¶n = 175. Chronic conditions: chronic bronchitis, heart disease or stroke, liver or kidney disease, diabetes, HIV, AIDS, or history of immunosuppression or 
cancer. RESEARCH
have opportunities to exchange genetic material with HA-
MRSA strains. CA-MRSA strains commonly contain toxin 
genes such as the PVL toxin gene, which may cause more 
serious nosocomial infections (32). In our study, 22 of the 
24 isolates characterized by PCR had the PVL gene.
Typically, patients with CA-MRSA infections have 
skin and soft tissue infections. However, this might not 
be the case for healthcare-onset CA-MRSA strain type in-
fections. Davis et al. (33) surmise that CA-MRSA strains 
exposed to healthcare settings may develop characteristics 
associated with HA-MRSA strains such as decreased ac-
cessory gene regulator function, inducible macrolide-lin-
cosamide-streptogrammin resistance, and non–β-lactam 
resistance patterns. Whether this translates into a clinical 
picture more consistent with HA-MRSA infections is un-
clear. According to our ﬁ  ndings, healthcare-onset CA-MR-
SA strain type infections were more likely than communi-
ty-onset CA-MRSA infections to be non-skin diseases and 
to occur in older populations, characteristics common to 
HA-MRSA disease (34).
Based on this study and that of Ma et al. (24), descrip-
tion of the Uruguayan CA-MRSA outbreak, USA1100 
or multilocus sequence type ST30 appears to be the pre-
dominant CA-MRSA strain circulating in Uruguay. This 
strain was identiﬁ  ed in Australia, New Zealand, Europe, 
the United States, and most recently Brazil (23,31,35). In 
the United States, ST30 accounted for 41% of CA-MRSA 
infections in 1 study in San Francisco (31). However, more 
recent data from that city suggest replacement of ST30 by 
ST8 (USA300) (36). Whether replacement of this strain in 
Uruguay will occur and what its effect on illness and mor-
tality rates would be remain to be seen.
The emergence of CA-MRSA in Uruguay has been 
rapid and is associated with signiﬁ  cant illness and mortal-
ity rates (37). Although most CA-MRSA strain type infec-
tions in Uruguay are of skin or soft tissue, primary pulmo-
nary disease appearing as necrotizing pneumonia has been 
described as well as skin or soft tissue infections leading 
to septic pulmonary embolic events (38,39). Of note, all 
isolates tested in our study were susceptible to multiple 
antimicrobial agents, most importantly TMP/SMX. On the 
basis of these ﬁ  ndings, TMP/SMX may be a viable, cost-
effective treatment option for many CA-MRSA infections 
(40).
This study was subject to limitations. Because we 
based our deﬁ  nition of healthcare-onset CA-MRSA strain 
type infections on time from hospital admission to culture 
and no evidence of infection on admission, misclassiﬁ  -
cation was possible. Patients admitted to the hospital for 
non-MRSA diagnoses may have had CA-MRSA strain skin 
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Table 2. Infection type for 182 hospitalized patients with community-onset CA-MRSA infections, centers A–D, Uruguay, 2003–2004*
Infection type† 
Total no. (%) infections, 
N = 269 
Healthcare-onset no. (%), 
n = 45 
Community-onset no. (%), 
n = 224  p value 
Skin (any)  169 (63)  10 (22)  159 (71)  <0.0001
 Impetigo  29 2 27
 Foliculitis/pustule  3 0 3
 Abscess  65 3 62
 Furunculosis  9 0 9
 Hidradenitis  1 0 1
 Cellulitis  49 2 47
 Abrasion  4 0 4
 Pressure  wound  4 0 4
 Trauma  wound  3 3 0
 Burn/necrotic  lesion  2 0 2
Respiratory  36 (13)  17 (38)  19 (9)  <0.0001
 Pneumonia‡  34 16 18
 Pleuritis  1 1 0
 Pleural  abscess  1 0 1
Bacteremia 24 (9)  3 (7)  21 (9)  0.78
Surgical site  23 (9)  12 (27)  11 (5)  <0.0001
Organ/space  11 (4)  1 (2)  10 (4)  0.70
 Septic  arthritis  6 1 5
 Osteomyelitis/myositis  5 0 5
Indwelling devices  3 (1)  1 (2)  2 (1)  0.42
 Catheter  infection  1 0 1
  Arteriovenous fistula infection  2 1 1
Otitis 2 (<1)  1 (2)  1 (<1)  0.31
Cerebral ventriculitis  1 (<1)  0 1 (<1)  1.00
*CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus.
†Infections are not mutually exclusive (269 infections in 182 patients). 
‡Pneumonia or tracheobronchitis. Community Strains of MRSA, Uruguay
infections on admission that were not documented or cul-
tured within the ﬁ  rst 48 hours. These skin infections would 
have been differentially misclassiﬁ  ed as healthcare-onset 
and would have diluted the relationship between non-skin 
infections and healthcare-onset CA-MRSA disease, there-
by underestimating our associations. In addition, because 
electronic laboratory records were unavailable in 3 of the 
4 facilities, unrecognized CA-MRSA cases potentially af-
fected the distribution of healthcare and community-onset 
CA-MRSA strain type cases. However, unless cases were 
systematically excluded, a selection bias was unlikely to 
have affected factors associated with healthcare-onset dis-
ease. Finally, because we suspected that CA-MRSA strains 
had entered the healthcare setting, we deﬁ  ned CA-MRSA 
on the basis of susceptibility patterns rather than epidemio-
logic risk factors. Without PFGE typing all isolates, it is not 
possible to determine if all included infections were con-
sistent with known CA-MRSA strain patterns. However, of 
the 24 isolates that were sent to CDC for characterization 
and met our deﬁ  nition of CA-MRSA, 22 (92%) were con-
sistent with CA-MRSA strain types.
This study describes characteristics of patients with 
healthcare-onset CA-MRSA strain type infections but does 
not identify the risk factors involved in nosocomial trans-
mission such as the presence of indwelling catheters, intu-
bation, certain procedures or surgeries, and speciﬁ  c units 
within the hospital. In addition, we do not know whether 
infections were acquired in the hospital or whether patients 
were colonized before arrival and infections subsequently 
developed in the hospital.
In conclusion, this study describes CA-MRSA emer-
gence in South America. In addition, similar to what is 
occurring in other countries, it demonstrates CA-MRSA 
strain type transmission within healthcare settings. Clini-
cians should be aware that CA-MRSA strains have entered 
the healthcare setting and cause skin as well as non-skin 
infections. These infections may respond to a variety of 
non–β-lactam antimicrobial agents. Adherence to infection 
control precautions while one is caring for patients with 
suspected or conﬁ  rmed CA-MRSA strain infections is criti-
cal for preventing transmission and further penetration of 
CA-MRSA in healthcare settings.
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